WEBVTT

1
00:00:02.000 --> 00:00:07.480
Survodutide brings GLP-1 and glucagon receptor activity into

2
00:00:07.480 --> 00:00:09.160
one peptide.

3
00:00:09.620 --> 00:00:12.820
Researchers are testing this combination for obesity and

4
00:00:12.820 --> 00:00:14.140
metabolic liver disease.

5
00:00:15.200 --> 00:00:19.540
It emerged from Boehringer Ingelheim and Zealand Pharma's partnership.

6
00:00:20.480 --> 00:00:24.220
Boehringer now leads global development, linking German and

7
00:00:24.220 --> 00:00:25.220
Danish research.

8
00:00:25.220 --> 00:00:30.820
A phase-three trial followed 725 adults without diabetes

9
00:00:30.820 --> 00:00:33.020
for 76 weeks.

10
00:00:33.620 --> 00:00:38.200
Average weight reductions were 12.2 and 13 percent,

11
00:00:38.500 --> 00:00:41.100
versus 5.4 percent with placebo.

12
00:00:41.810 --> 00:00:44.610
Body weight does not directly measure liver fat.

13
00:00:45.320 --> 00:00:49.800
Separate liver research used magnetic resonance imaging to measure fat.

14
00:00:50.700 --> 00:00:54.840
Lee Kaplan and colleagues treated 216 adults with

15
00:00:54.840 --> 00:00:58.120
obesity and at risk fatty liver disease.

16
00:00:58.120 --> 00:01:03.280
At 48 weeks, 68.5 percent reached at least

17
00:01:03.280 --> 00:01:06.520
a 30 percent relative liver fat reduction, versus

18
00:01:06.520 --> 00:01:09.240
28.6 percent with placebo.

19
00:01:10.500 --> 00:01:14.000
These analyses include treatment discontinuation.

20
00:01:14.360 --> 00:01:17.560
Tolerability can affect whether people continue treatment.

21
00:01:17.920 --> 00:01:22.380
Gastrointestinal symptoms were common and sometimes led to treatment stopping.

22
00:01:23.420 --> 00:01:26.620
Less liver fat does not by itself prove

23
00:01:26.620 --> 00:01:28.340
reversal of fibrosis.

24
00:01:28.340 --> 00:01:34.480
At the October 14, 2026 cutoff, survodutide remains

25
00:01:34.480 --> 00:01:35.720
investigational.

26
00:01:36.580 --> 00:01:40.940
Longer-term studies must establish lasting benefits and risks.

27
00:01:41.000 --> 00:01:44.480
Weight and liver-fat measurements are part of the evidence.

28
00:01:44.970 --> 00:01:48.430
Lasting health benefits remain the key question.

29
00:01:48.780 --> 00:01:50.050
Peptides in 2.

30
00:01:50.450 --> 00:01:52.230
World Peptide Foundation.

31
00:01:52.580 --> 00:01:54.940
Every experience matters.